tbuckley/cabot-search huggingface dataset:
Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA
Authors: Min Kang, Bo Tang, Jixi Li, Ziyan Zhou, Kang Liu, Rensheng Wang, Ziyan Jiang, Fangfang Bi, David Patrick, Dongin Kim, Anirban K. Mitra, Yang Yang-Hartwich
Journal: Molecular Cancer (2020)

Abstract Background Very few proteins encoded by the presumed non-coding RNA transcripts have been identified. Their cellular functions remain largely unknown. This study identifies the tumor-suppressor function of a novel microprotein encoded by the precursor of miR-34a. It consists of 133 amino acid residues, thereby named as miPEP133 (pri-microRNA encoded peptide 133). Methods We overexpressed miPEP133 in nasopharyngeal carcinoma (NPC), ovarian cancer and cervical cancer cell lines to determine its effects on cell growth, apoptosis, migration, or invasion. Its impact on tumor growth was evaluated in a xenograft NPC model. Its prognostic value was analyzed using NPC clinical samples. We also conducted western blot, immunoprecipitation, mass spectrometry, confocal microscopy and flow cytometry to determine the underlying mechanisms of miPEP133 function and regulation. Results miPEP133 was expressed in normal human colon, stomach, ovary, uterus and pharynx. It was downregulated in cancer cell lines and tumors. miPEP133 overexpression induced apoptosis in cancer cells and inhibited their migration and invasion. miPEP133 inhibited tumor growth in vivo. Low miPEP133 expression was an unfavorable prognostic marker associated with advanced metastatic NPC. Wild-type p53 but not mutant p53 induced miPEP133 expression. miPEP133 enhanced p53 transcriptional activation and miR-34a expression. miPEP133 localized in the mitochondria to interact with mitochondrial heat shock protein 70kD (HSPA9) and prevent HSPA9 from interacting with its binding partners, leading to the decrease of mitochondrial membrane potential and mitochondrial mass. Conclusion miPEP133 is a tumor suppressor localized in the mitochondria. It is a potential prognostic marker and therapeutic target for multiple types of cancers.
Kidney GATA3+ regulatory T cells play roles in the convalescence stage after antibody-mediated renal injury
Authors: Ryota Sakai, Minako Ito, Kyoko Komai, Mana Iizuka-Koga, Kazuhiko Matsuo, Takashi Nakayama, Osamu Yoshie, Koichi Amano, Hiroshi Nishimasu, Osamu Nureki, Masato Kubo, Akihiko Yoshimura
Journal: Cellular and Molecular Immunology (2020)

FoxP3
Abstract 16481: Is the Neutrophil-To-Lymphocyte Ratio a Predictor of Outcomes in Acute Stroke?
Authors: Ezequiel Munoz, Jose Sleiman, Juan Del Cid Fratti, Miguel Salazar, Victor Prado, Harry E Fuentes, Yilen K Ng Wong, Sagar Ranka, Muhammad T Ayub, Juan P Rey, Andres Mendez, Xavier Andrade, Ali Ayoub, Luis H Paz
Journal: Circulation (2018)

Introduction: Inflammation plays a pivotal role in the pathogenesis and outcomes of acute stroke. Multiple markers such as C-reactive protein, erythrocyte sedimentation rate and white blood cell co...
Maurice McConnell Burrows
Authors: John Sprigge
Journal: BMJ (2020)

Maurice McConnell Burrows was born in Bangor, County Down, the elder of two sons of Hugh and Maisie Burrows. Both sons would become distinguished doctors. Maurice took up anaesthesia early in his career, and studied at the Liverpool School of Anaesthesia. He spent two years as an anaesthetist in national service, where he was promoted to the rank of major, before being appointed consultant to the Wirral hospitals in 1958. Very soon his colleagues recognised his potential skills in representing their interests, which he would go on to employ locally, regionally, and then nationally. Throughout his anaesthetic career, he did not give up his …
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
Authors: Anne L. Peters, Darren K. McGuire, Thomas Danne, Jake A. Kushner, Helena W. Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J. Davies, Pablo Lapuerta
Journal: Diabetes Care (2020)

OBJECTIVE To evaluate the incidence and risk factors for diabetic ketoacidosis (DKA) and related adverse events (AEs) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin. RESEARCH DESIGN AND METHODS Data from two identically designed, 52-week, randomized studies were pooled and analyzed for DKA, changes in β-hydroxybutyrate (BHB), and percentage of patients with BHB &amp;gt;0.6 and &amp;gt;1.5 mmol/L. The patients were administered placebo, sotagliflozin 200 mg, or sotagliflozin 400 mg once daily. RESULTS A total of 191 ketosis-related AEs were reported, and 98 underwent adjudication. Of these, 37 events (36 patients) were adjudicated as DKA, with an exposure-adjusted incidence rate of 0.2, 3.1, and 4.2 events per 100 patient-years for placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively. No patient died of a DKA event. From a baseline BHB of ∼0.13 mmol/L, sotagliflozin treatment led to a small median increase over 52 weeks (≤0.05 mmol/L at all time points). Of sotagliflozin-treated patients, approximately 47% and 7% had ≥1 BHB measurement &amp;gt;0.6 mmol/L and &amp;gt;1.5 mmol/L, respectively (vs. 20% and 2%, respectively, of placebo-treated patients). Subsequent to the implementation of a risk mitigation plan, annualized DKA incidence was lower versus preimplementation in both the sotagliflozin 200 and 400 mg groups. CONCLUSIONS In patients with type 1 diabetes, confirmed DKA incidence increased when sotagliflozin was added to insulin compared with insulin alone. A lower incidence of DKA was observed following the implementation of an enhanced risk mitigation plan, suggesting that this risk can be managed with patient education.
Abstract 8930: Acute and Long-term Outcome of the Magnetic Navigation System for Ablation of Arrhythmias in a Large Series of Patients
Authors: Ferdi Akca, Tamas Bauernfeind, Bruno Schwagten, Natasja M De Groot, Luc Jordaens, Tamas Szili-Torok
Journal: Circulation (2012)

Objective: Evaluate safety and efficacy of Magnetic Navigation System (MNS) in a large series of patients during long-term follow up. Background: MNS has the potential for improving safety and efficacy based on atraumatic catheter design and superior navigation capabilities. Methods: In this prospective registry, 1.266 consecutive patients underwent ablation. Patients were divided into two age- and sex-matched groups. Ablations were performed either using MNS (group MNS, 457) or conventional manual ablation (group MAN, 809). Following parameters were analyzed: acute success rate, fluoroscopy time, procedure time, complications (major: pericardial tamponade, permanent atrioventricular (AV) block, stroke, pulmonary embolism, major bleeding, death; minor: minor bleeding, temporary AV block). Recurrence rate was assessed during an average follow up of 24±14 months. Subgroup analysis was performed for the following groups: isthmus dependent and atypical atrial flutter, atrial tachycardia, AV nodal re-entrant tachycardia, circus movement tachycardia, atrial fibrillation and ventricular tachycardia (VT). Results: MNS was equally effective as MAN in acute success rate for overall groups (91,5% vs. 91,5%, p=ns). MNS was more successful for VTs (85,5% vs. 67,1%, p=0.006) and AVRT (96,3% vs. 88,4%, p=0.05). In the MNS group less fluoroscopy was used for AVNRT (12±7 vs. 27±19, p&lt;0.001) and VT (26±19 vs. 48±29, p&lt;0.001), however, longer fluoroscopy times were registered for AF (58±19 vs. 47±25, p&lt;0.001). Procedure times for the overall group were longer in the MNS group (191±92 vs. 173±77 min, p=0.003). During follow up no differences in recurrence were observed between MNS and MAN for the overall population and the subgroups. MNS was associated with less major complications (1,1% vs. 3,7%, p=0.004). The total numbers of complications were lower in group MNS (5,0% vs. 9,8%, p=0.002). Conclusions: Our data suggest that the use of MNS improves safety without compromising efficiency of ablations. MNS is more effective than manual ablation for VTs and AVRTs.
Double-sided anchoring of a newly placed mid-gastric metal stent using novel dedicated over-the-scope clips to allow safe through-the-stent ERCP
Authors: Vincent Zimmer
Journal: Endoscopy (2020)

The patient was an 85-year-old woman who had been diagnosed with advanced gastric cancer including diffuse peritoneal spread 3 months previously. She had recently been admitted after four cycles of palliative chemotherapy because of progressive signs of luminal occlusion, as well as jaundice. Laboratory assessment was significant for increased cholestasis parameters (γ-glutamyltransferase 1084 U/L, alkaline phosphatase 977 U/L, bilirubin 0.6 mg/dL) and minor systemic inflammation (C-reactive protein 3.4 mg/dL). Therefore, antibiotic treatment was commenced for suspected cholangitis.
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy
Authors: Anna S. Lok, Robert Perrillo, Christina M. Lalama, Michael W. Fried, Steven H. Belle, Marc G. Ghany, Mandana Khalili, Robert J. Fontana, Richard K. Sterling, Norah Terrault, Jordan J. Feld, Adrian M. Di Bisceglie, Daryl T.Y. Lau, Mohamed Hassan, Harry L.A. Janssen
Journal: Hepatology (2020)

Background and Aims Outcomes of persons with chronic hepatitis B virus (HBV) infection in the era of antiviral therapy (AVT) are not well characterized. We determined the incidence and factors associated with clinical outcomes in a multiethnic, North American cohort of adults with chronic HBV infection, who were not on AVT at enrollment. Approach and Results Adults with chronic HBV infection, not receiving AVT, and without a history of decompensation, HCC, or liver transplantation (LT), were prospectively followed. Participants with known human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D virus (HDV) coinfection were excluded. During follow‐up, treatment could be initiated per standard of care. Clinical outcomes included: incident cirrhosis, decompensation, HCC, OLT, and HBV‐related death. Among 1,418 participants analyzed, 51.5% were women, median age was 41.1 years, 75% were Asian, 10% White, 13% Black, 24% HBeAg(+), and 1.5% cirrhosis at baseline. During the study, 274 started treatment, 83 had an alanine aminotransferase flare, 118 of 330 initially HBeAg(+) became HBeAg(−), and 90 of 1,329 became HBsAg(−). After 6,641 person‐years follow‐up, 8 participants (4 of 21 with baseline cirrhosis) had 12 clinical outcomes (2 decompensation, 5 HCC, 2 OLT, and 3 HBV‐related deaths) and 19 of 1,397 had incident cirrhosis. Twenty‐one of 26 participants had first outcome before treatment, none had become HBsAg(−), whereas 5/9 HBeAg(+) had become HBeAg(−) at time of first outcome. Cumulative percentage of clinical outcomes was 16% at year 4 in participants with baseline cirrhosis and 2% (including incident cirrhosis) at year 7 in those without. Conclusions Incidence of adverse outcomes was low in this closely monitored, large cohort of North American adults with predominantly inactive, chronic HBV without cirrhosis. Our data highlight the benefits of HBsAg loss and the importance of early diagnosis and treatment to prevent cirrhosis and other complications of chronic HBV infection.
Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study
Authors: Seung Won Lee, Jee Myung Yang, Sung Yong Moon, In Kyung Yoo, Eun Kyo Ha, So Young Kim, Un Min Park, Sejin Choi, Sang-Hyuk Lee, Yong Min Ahn, Jae-Min Kim, Hyun Yong Koh, Dong Keon Yon
Journal: The Lancet Psychiatry (2020)
Airway Hyperresponsiveness In COPD : A Marker Of Asthma-COPD Overlap Syndrome?
Authors: R. Tkacova, D. Dai, J.M. Vonk, J. Leung, P.S. Hiemstra, M. van den Berge, L. Kunz, Z. Hollander, D.P. Tashkin, R.A. Wise, J.E. Connett, R.T. Ng, B.M. McManus, S. Man, D.S. Postma, D.D. Sin
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
THE EYE AS A NON-INVASIVE WINDOW TO THE MICROCIRCULATION IN CIRRHOSIS: A PROSPECTIVE COHORT STUDY
Authors: Fiona J. Gifford, Francesca Moroni, Tariq Farrah, Kirstie Hetherington, Tom J. MacGillivray, Peter Hayes, Neeraj Dhaun, Jonathan Andrew Fallowfield
Journal: Hepatology (2019)
Specific IgE antibodies to synthetic glycan structures in a helminth-endemic area of Indonesia
Authors: F. Hamid, E. Asuming-Brempong, A.S. Amoah, E. Sartono, N.C. Reichardt, R. van Ree, A. van Diepen, C.H. Hokke, M. Yazdanbakhsh
Journal: Allergy (2015)
Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 — COVID-NET, 13 States, March 1–August 22, 2020
Authors: Miranda J. Delahoy, Michael Whitaker, Alissa O’Halloran, Shua J. Chai, Pam Daily Kirley, Nisha Alden, Breanna Kawasaki, James Meek, Kimberly Yousey-Hindes, Evan J. Anderson, Kyle P. Openo, Maya L. Monroe, Patricia A. Ryan, Kimberly Fox, Sue Kim, Ruth Lynfield, Samantha Siebman, Sarah Shrum Davis, Daniel M. Sosin, Grant Barney, Alison Muse, Nancy M. Bennett, Christina B. Felsen, Laurie M. Billing, Jessica Shiltz, Melissa Sutton, Nicole West, William Schaffner, H. Keipp Talbot, Andrea George, Melanie Spencer, Sascha Ellington, Romeo R. Galang, Suzanne M. Gilboa, Van T. Tong, Alexandra Piasecki, Lynnette Brammer, Alicia M. Fry, Aron J. Hall, Jonathan M. Wortham, Lindsay Kim, Shikha Garg, Mirasol Apostol, Susan Brooks, Ashley Coates, Linda Frank, Brooke Heidenga, Kareena Hundal, Joelle Nadle, Sherry Quach, Jeremy Roland, Maria Rosales, Isaac Armistead, Rachel Herlihy, Sarah McLafferty, Adam Misiorski, Christina Parisi, Danyel Olson, Carol Lyons, Amber Maslar, Paula Clogher, David Blythe, Alicia Brooks, Rachel Park, Michelle Wilson, Erica Bye, Kathryn Como-Sabetti, Richard Danila, Maureen Sullivan, Kathy M. Angeles, Melissa Christian, Nancy Eisenberg, Caroline Habrun, Emily B. Hancock, Sarah A. Khanlian, Meaghan Novi, Yadira Salazar-Sanchez, Elizabeth Dufort, Nancy Spina, Ama Owusu-Dommey, Tiffanie Markus, Ryan Chatelain, Laine McCullough, Jake Ortega, Andrea Price, Ashley Swain, Anita Kambhampati, Seth Meador
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Pregnant women might be at increased risk for severe coronavirus disease 2019 (COVID-19) (1,2). The COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) (3) collects data on hospitalized pregnant women with laboratory-confirmed SARS-CoV-2, the virus that causes COVID-19; to date, such data have been limited. During March 1-August 22, 2020, approximately one in four hospitalized women aged 15-49 years with COVID-19 was pregnant. Among 598 hospitalized pregnant women with COVID-19, 54.5% were asymptomatic at admission. Among 272 pregnant women with COVID-19 who were symptomatic at hospital admission, 16.2% were admitted to an intensive care unit (ICU), and 8.5% required invasive mechanical ventilation. During COVID-19-associated hospitalizations, 448 of 458 (97.8%) completed pregnancies resulted in a live birth and 10 (2.2%) resulted in a pregnancy loss. Testing policies based on the presence of symptoms might miss COVID-19 infections during pregnancy. Surveillance of pregnant women with COVID-19, including those with asymptomatic infections, is important to understand the short- and long-term consequences of COVID-19 for mothers and newborns. Identifying COVID-19 in women during birth hospitalizations is important to guide preventive measures to protect pregnant women, parents, newborns, other patients, and hospital personnel. Pregnant women and health care providers should be made aware of the potential risks for severe COVID-19 illness, adverse pregnancy outcomes, and ways to prevent infection.
Quantitative determination of 64Cu-liposome accumulation at inflammatory and infectious sites: Potential for future theranostic system
Authors: Anne Skovsbo Clausen, Daniella Elisabet Østergaard, Petter Holmberg, Jonas Rosager Henriksen, Johan Tham, Peter Panduro Damborg, Andreas I. Jensen, Andreas Kjaer, Anders Elias Hansen, Thomas Lars Andresen
Journal: Journal of Controlled Release (2020)
Characteristics of COVID-19 in Homeless Shelters
Authors: Julia H. Rogers, Amy C. Link, Denise McCulloch, Elisabeth Brandstetter, Kira L. Newman, Michael L. Jackson, James P. Hughes, Janet A. Englund, Michael Boeckh, Nancy Sugg, Misja Ilcisin, Thomas R. Sibley, Kairsten Fay, Jover Lee, Peter Han, Melissa Truong, Matthew Richardson, Deborah A. Nickerson, Lea M. Starita, Trevor Bedford, Helen Y. Chu
Journal: Annals of Internal Medicine (2020)

Homeless shelters are a high-risk setting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission because of crowding and shared hygiene facilities.
Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting
Authors: Elizabeth A Bemis, M Kristen Demoruelle, Jennifer A Seifert, Kristen J Polinski, Michael H Weisman, Jane H Buckner, Peter K Gregersen, Ted R Mikuls, James R ODell, Richard M Keating, Kevin D Deane, V Michael Holers, Jill M Norris
Journal: Annals of the Rheumatic Diseases (2020)

Little is known about the likelihood of developing inflammatory arthritis (IA) in individuals who screen autoantibody positive (aAb+) in a non-clinical research setting.
Diabetes in ageing: pathways for developing the evidence base for clinical guidance
Authors: Medha N Munshi, Graydon S Meneilly, Leocadio Rodríguez-Mañas, Kelly L Close, Paul R Conlin, Tali Cukierman-Yaffe, Angus Forbes, Om P Ganda, C Ronald Kahn, Elbert Huang, Lori M Laffel, Christine G Lee, Sei Lee, David M Nathan, Naushira Pandya, Richard Pratley, Robert Gabbay, Alan J Sinclair
Journal: The Lancet Diabetes & Endocrinology (2020)
We Are People, Not Clusters!
Authors: Edwin J. Bernard, Alexander McClelland, Barb Cardell, Cecilia Chung, Marco Castro-Bojorquez, Martin French, Devin Hursey, Naina Khanna, Mx Brian Minalga, Andrew Spieldenner, Sean Strub
Journal: The American Journal of Bioethics (2020)

As advocates and scholars, including people living with HIV, we have been engaged in a critical debate over molecular HIV surveillance (MHS), as well as its antecedent and future practices. We have...
Biodegradable Metal–Organic Framework‐Based Microrobots (MOFBOTs)
Authors: Anastasia Terzopoulou, Xiaopu Wang, Xiang‐Zhong Chen, Mario Palacios‐Corella, Carlos Pujante, Javier Herrero‐Martín, Xiao‐Hua Qin, Jordi Sort, Andrew J. deMello, Bradley J. Nelson, Josep Puigmartí‐Luis, Salvador Pané
Journal: Advanced Healthcare Materials (2020)

Microrobots and metal-organic frameworks (MOFs) have been identified as promising carriers for drug delivery applications. While clinical applications of microrobots are limited by their low drug loading efficiencies and the poor degradability of the materials used for their fabrication, MOFs lack motility and targeted drug delivery capabilities. The combination of these two fields marks the beginning of a new era; MOF-based small-scale robots (MOFBOTs) for biomedical applications. Yet, biodegradability is a major hurdle in the field of micro- and nanoswimmers including small-scale robots. Here, a highly integrated MOFBOT that is able to realize magnetic locomotion, drug delivery, and selective degradation in cell cultures is reported for the first time. The MOF used in the investigations does not only allow a superior loading of chemotherapeutic drugs and their controlled release via a pH-responsive degradation but it also enables the controlled locomotion of enzymatically biodegradable gelatin-based helical microrobots under magnetic fields. The degradation of the integrated MOFBOT is observed after two weeks, when all its components fully degrade. Additionally, drug delivery studies performed in cancer cell cultures show reduced viability upon delivery of Doxorubicin within short time frames. This MOFBOT system opens new avenues for highly integrated fully biodegradable small-scale robots.
Primer on Biomarker Discovery in Cardio-Oncology
Authors: June-Wha Rhee, Bonnie Ky, Saro H. Armenian, Clyde W. Yancy, Joseph C. Wu
Journal: JACC CardioOncology (2020)

Remarkable progress in cancer treatments has resulted in improved long-term survival. However, cardiovascular complications related to these therapies may result in treatment interruptions and worse oncologic and cardiovascular outcomes. Early diagnosis and management of cancer therapy
Patient-Perpetrated Harassment Policies in Patient Bills of Rights and Responsibilities at US Academic Medical Centers
Authors: Elizabeth M. Viglianti, Lisa M. Meeks, Andrea L. Oliverio
Journal: JAMA Network Open (2020)

This cross-sectional study examines the degree to which patient bills of rights and responsibilities from 50 academic hospitals in the US communicate a zero-tolerance policy against patient-perpetrated sexual harassment toward health care professionals.
SZ alpha-1 antitrypsin deficiency and pulmonary disease: more like MZ, not like ZZ
Authors: Alessandro N Franciosi, Tomás P Carroll, Noel G McElvaney
Journal: Thorax (2020)

The ZZ genotype of alpha-1 antitrypsin deficiency (AATD) is associated with COPD regardless of smoking. Heterozygous MZ-AATD is recognised as a moderate deficiency state, increasing the risk of COPD only among smokers. The risk attributable to SZ-AATD remains debated. We compared 486 AATD-registry participants, to determine whether SZ-AATD was associated with pulmonary outcomes more comparable to MZ-AATD or ZZ-AATD. We found no significant differences between MZ and SZ individuals regardless of never-smoking/ever-smoking (p&gt;0.05 for all). ZZ-AATD was associated with lower FEV1 pp than SZ, regardless of never-smoking/ever-smoking, as well as an increased OR of lung-index status and visually defined emphysema on CT (p≤0.002 for all). In our registry cohort SZ-AATD is associated with a risk of lung disease comparable to MZ, not ZZ-AATD.
Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome
Authors: Rosaura Esteve-Puig, Fina Climent, David Piñeyro, Eva Domingo-Domènech, Veronica Davalos, Maite Encuentra, Anna Rea, Nadia Espejo-Herrera, Marta Soler, Miguel Lopez, Vanessa Ortiz-Barahona, Gustavo Tapia, José-Tomás Navarro, Joan Cid, Lourdes Farré, Alberto Villanueva, Isolda Casanova, Ramon Mangues, Pablo Santamarina-Ojeda, Agustín F. Fernández, Mario F. Fraga, Miguel Angel Piris, Nitzan Kol, Chen Avrahami, Sharon Moshitch-Moshkovitz, Gideon Rechavi, Anna Sureda, Manel Esteller
Journal: Blood (2020)